Search - tctmd.com

Displaying 81 - 100 of 109

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for September 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

September 30, 2017

New Performance and Quality Metrics for STEMI and NSTEMI Care

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

September 08, 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

News Conference News ESC 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

September 01, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

ESC Updates Guidelines for Treating STEMI Patients

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

July 24, 2017

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

News Daily News

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

May 04, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

News Daily News

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

March 10, 2017

Ticagrelor May Be Useful for Secondary Prevention After Stroke, TIA If Initial Event Is Related to Atherosclerosis

News Conference News ISC 2017

Ticagrelor May Be Useful After Stroke, TIA if Event Related to Atherosclerosis

February 28, 2017

PFO and Migraine? New Study Zeros in on Atrial Septal Aneurysms

News Daily News

¿FOP y Migrañas? Un Nuevo Estudio se Centra en los Aneurismas del Tabique Interauricular

December 08, 2016

PFO and Migraine? New Study Zeros in on Atrial Septal Aneurysms

News Daily News

PFO and Migraine? New Study Zeros in on Atrial Septal Aneurysms

December 08, 2016

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

November 28, 2016

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

November 09, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.